Transcranial Magnetic Stimulator Sales

Transcranial Magnetic Stimulator Sales Market Outlook

The global Transcranial Magnetic Stimulator (TMS) market is poised to witness significant growth, with a projected market size of approximately USD 1.5 billion by 2035, expanding at a compound annual growth rate (CAGR) of around 12.5% during the forecast period of 2025 to 2035. This growth can largely be attributed to the increasing prevalence of neurological disorders, rising awareness regarding non-invasive treatment options, and advancements in TMS technology. Moreover, the growing acceptance of TMS as an effective therapeutic approach for conditions such as depression and chronic pain management has fueled demand. Additionally, the increase in research and development activities aimed at enhancing the efficacy and safety of TMS devices has contributed positively to market expansion. Factors such as government initiatives to promote mental health treatment and the integration of TMS with other therapeutic modalities are further expected to drive market growth in the coming years.

Growth Factor of the Market

The Transcranial Magnetic Stimulator market is primarily driven by an increasing prevalence of mental health disorders, particularly major depressive disorder (MDD) and anxiety-related conditions. As the stigma surrounding mental health continues to diminish, more individuals are seeking effective treatments, leading to a surge in TMS applications. Furthermore, the growing body of clinical evidence supporting the efficacy of TMS in treating depression has resulted in wider acceptance among healthcare providers and patients alike. Another significant growth factor is the technological advancements in TMS devices, which have improved treatment precision and reduced session times. The expansion of reimbursement policies for TMS treatments by insurance providers has also enhanced accessibility, encouraging more patients to consider this innovative therapy. Additionally, the rise in collaborations between research institutions and healthcare providers to develop novel TMS applications is likely to present further opportunities for market growth.

Key Highlights of the Market

• The global TMS market is projected to reach USD 1.5 billion by 2035, growing at a CAGR of 12.5%.
• Repetitive Transcranial Magnetic Stimulation (rTMS) accounts for the largest market share due to its established efficacy in treating depression.
• North America holds a significant market share, driven by an increasing number of healthcare facilities offering TMS treatments.
• Advancements in TMS technology, including portable and at-home TMS devices, are expected to enhance market penetration.
• The growing awareness of mental health issues and the demand for non-invasive treatments are propelling market growth.

By Product Type

Repetitive Transcranial Magnetic Stimulation (rTMS)

Repetitive Transcranial Magnetic Stimulation (rTMS) is the most widely used form of TMS and holds a significant market share. rTMS utilizes repetitive magnetic pulses to stimulate specific regions of the brain, primarily targeting the prefrontal cortex, which is associated with mood regulation. This method has been extensively studied and is FDA-approved for the treatment of major depressive disorder, making it a favored choice among healthcare providers. The efficacy of rTMS in reducing depressive symptoms has prompted its integration into various treatment protocols, thus expanding its adoption in clinical settings. The versatility of rTMS in addressing different neurological and psychiatric conditions further enhances its market prospects. As researchers continue to explore its therapeutic potential, it is likely that rTMS will remain a leading product type in the TMS market.

Theta Burst Stimulation (TBS)

Theta Burst Stimulation (TBS) is a relatively recent advancement in TMS technology that employs a specific pattern of stimulation designed to enhance the efficiency of neural modulation. TBS has gained popularity due to its ability to deliver a similar therapeutic effect as conventional rTMS while substantially reducing treatment duration. The unique protocol used in TBS can achieve results in a shorter timeframe, making it an attractive option for clinics aiming to optimize patient throughput. As studies continue to validate its effectiveness across a range of conditions, including chronic pain and neurodegenerative diseases, TBS is expected to carve out a significant segment within the TMS market. The ongoing research into its applications and potential for customization further positions TBS as a promising solution in the evolving landscape of TMS therapies.

Deep Transcranial Magnetic Stimulation (dTMS)

Deep Transcranial Magnetic Stimulation (dTMS) represents an innovative approach to TMS that enables stimulation of deeper brain structures compared to conventional TMS methods. This technique utilizes specially designed coils that can penetrate deeper into the brain, potentially allowing for the treatment of a broader range of neurological disorders. dTMS has gained traction for its application in severe depression cases where traditional therapies may not be effective. As dTMS continues to undergo clinical trials, its promising results in treating conditions such as obsessive-compulsive disorder (OCD) are expected to drive market growth. The increasing number of clinical studies validating the safety and efficacy of dTMS continues to attract attention from both healthcare providers and patients, positioning it as a vital product type in the TMS market.

Quadripulse Stimulation (QPS)

Quadripulse Stimulation (QPS) is an advanced TMS technique that allows for the modulation of brain activity through a specific pattern of pulses. QPS is particularly noteworthy for its ability to induce long-term potentiation (LTP) and long-term depression (LTD) in neural circuits, which are critical mechanisms in learning and memory. The unique properties of QPS have demonstrated potential therapeutic benefits for various neurological disorders, including stroke rehabilitation and cognitive enhancement. As more research highlights its capabilities, QPS is anticipated to become an essential component of the TMS market. The growing interest in cognitive therapies and brain modulation techniques further supports the potential for QPS to find its place among established TMS applications.

Others

This category encompasses a variety of other TMS techniques and specialized devices that do not fit neatly into the aforementioned classifications. These may include personalized, targeted TMS approaches that utilize adaptive algorithms to tailor treatment to individual patient needs. The emergence of wearable TMS devices, which allow for at-home administration, also falls within this segment. As the demand for customized therapies grows, innovations in the "Others" category are likely to drive interest and market share. This segment is critical as it reflects the evolving landscape of TMS applications and the increasing demand for flexible, patient-centered solutions in mental health treatment.

By Application

Depression

The application of Transcranial Magnetic Stimulation in treating depression is one of the most established and widely accepted uses of TMS technology. Clinical studies have shown that rTMS can significantly alleviate symptoms of major depressive disorder, particularly in patients who have not responded to traditional pharmacological treatments. As a result, depression accounts for a substantial share of the TMS market, with ongoing research seeking to optimize treatment protocols and expand its applicability. The growing recognition of mental health conditions and the importance of effective interventions have driven demand for TMS as an alternative or adjunctive therapy for depression, thereby supporting market growth. Furthermore, as more healthcare practitioners integrate TMS into their practice, the landscape for depression treatment is expected to continue evolving, solidifying TMS's role as a frontline therapeutic option.

Pain Management

Transcranial Magnetic Stimulation has emerged as a promising non-invasive option for pain management, particularly in conditions such as fibromyalgia, chronic migraines, and other neuropathic pain syndromes. The application of TMS for pain relief works by modulating pain pathways in the brain, thereby reducing the perception of pain. This innovative approach is becoming increasingly recognized for its potential to provide relief for patients who have not found success with conventional pain management strategies, such as pharmacotherapy or physical therapy. The growing body of clinical evidence supporting TMS use in pain management continues to expand, attracting interest from both practitioners and patients. As healthcare systems seek to address the opioid crisis and find effective alternatives, TMS stands out as a viable option, which is likely to drive growth in this application segment.

Neurology

The application of Transcranial Magnetic Stimulation in neurology has broadened significantly, with emerging studies exploring its use in conditions such as Parkinson's disease, multiple sclerosis, and traumatic brain injuries. TMS has the ability to stimulate specific regions of the brain, thereby potentially restoring functional connectivity and improving motor and cognitive functions. Neurorehabilitation through TMS is gaining traction as a complementary treatment approach, particularly in rehabilitation settings. As healthcare providers increasingly recognize the role of neuromodulation in addressing various neurological conditions, the demand for TMS applications in neurology is expected to grow. Research will continue to unveil the potential benefits of TMS in enhancing recovery outcomes, thereby reinforcing its importance in neurological care.

Psychiatry

In the field of psychiatry, Transcranial Magnetic Stimulation is being investigated for its efficacy in treating a range of mental health disorders beyond depression, including anxiety disorders, bipolar disorder, and post-traumatic stress disorder (PTSD). The ability of TMS to modulate neural circuits linked to emotional regulation has opened new avenues for psychiatric treatment. As research into the neurobiological underpinnings of psychiatric disorders advances, TMS is becoming recognized as an innovative tool for addressing complex psychiatric conditions that often resist conventional therapies. The growing acceptance of TMS within psychiatric treatment settings, coupled with increasing clinical evidence, positions it as a valuable addition to the psychiatrist's therapeutic arsenal, facilitating improvements in patient outcomes.

Others

The "Others" category encompasses a variety of TMS applications that extend beyond the traditional therapeutic uses for depression, pain management, and neurological disorders. These applications may include cognitive enhancement, addiction treatment, and studies investigating the impact of TMS on cognitive impairment in aging populations. The versatility of TMS technology lends itself to numerous exploratory applications, which are being researched by academic and clinical institutions worldwide. As the understanding of TMS's potential benefits grows, this segment is expected to witness increased interest and investment, paving the way for innovative therapies that address a range of mental health and cognitive challenges.

By Distribution Channel

Hospitals

Hospitals represent a primary distribution channel for Transcranial Magnetic Stimulators, serving as key locations for the administration of TMS therapies. Many hospitals have established specialized psychiatric and neurological units capable of providing TMS as part of comprehensive treatment plans for patients. The integration of TMS into hospital settings is facilitated by the availability of trained professionals, advanced infrastructure, and the ability to monitor patients post-treatment effectively. Additionally, hospitals benefit from the backing of insurance reimbursement for TMS procedures, making it a viable treatment option for a broader patient population. As the demand for mental health services continues to rise, hospitals are expected to further increase their offerings of TMS therapies, solidifying their role as a significant distribution channel in the market.

Specialty Clinics

Specialty clinics dedicated to mental health and neurological disorders are also emerging as prominent players in the distribution of Transcranial Magnetic Stimulators. These clinics often focus on delivering specialized care, making them an ideal setting for TMS treatments. The personalized approach offered in specialty clinics allows for thorough evaluations and tailored treatment plans, which can enhance patient outcomes. Furthermore, as patient awareness of TMS increases, specialty clinics are becoming a preferred choice for individuals seeking targeted non-invasive therapies. The expansion of these clinics is anticipated to provide greater access to TMS, thereby catering to the growing demand for mental health treatments in local communities. This trend will likely enhance the overall market growth for TMS devices.

Ambulatory Surgical Centers

Ambulatory Surgical Centers (ASCs) are increasingly recognized as a suitable environment for administering TMS treatments due to their capacity for outpatient care. ASCs offer patients the advantage of receiving TMS therapy in a lower-cost setting compared to traditional hospital environments. This accessibility, coupled with the ability to schedule treatments with minimal wait times, has made ASCs an attractive option for individuals seeking TMS. The growing preference for outpatient services in healthcare is propelling the presence of TMS offerings in these centers. As healthcare systems shift towards value-based care models, ASCs are expected to play a crucial role in facilitating access to TMS, contributing to the overall growth of the market.

Research Institutes

Research institutes are pivotal in the advancement of Transcranial Magnetic Stimulation technology and its applications. Many research organizations are engaged in clinical trials aimed at investigating the efficacy of TMS for various neurological and psychiatric conditions, enabling the development of evidence-based practices. The collaboration between research institutes and healthcare facilities can lead to the commercialization of innovative TMS devices and techniques, thereby expanding market potential. These institutes often serve as training centers for practitioners, ensuring that the latest TMS protocols are disseminated throughout clinical networks. As research efforts continue to uncover new applications for TMS, the role of research institutes in shaping market dynamics will remain significant.

Others

The "Others" category includes various distribution channels that may not fit into the traditional categories of hospitals, specialty clinics, ASCs, or research institutes. This can encompass online platforms that facilitate the sale and distribution of TMS devices, as well as alternative healthcare facilities that are beginning to offer TMS as part of their treatment options. The increasing trend of telemedicine and digital health solutions has also created opportunities for remote monitoring and virtual consultations regarding TMS therapy. As the market landscape evolves, these alternative distribution channels are likely to gain traction, catering to the demands of a tech-savvy patient population seeking convenient access to TMS treatments.

By Region

The regional analysis of the Transcranial Magnetic Stimulator market reveals significant variations in market size and growth potential across different areas. North America dominates the TMS market, accounting for approximately 45% of the global share, primarily due to the high prevalence of mental health disorders, well-established healthcare infrastructure, and favorable reimbursement policies. The market in this region is expected to grow at a CAGR of 12.8% from 2025 to 2035, driven by the increasing number of TMS treatment centers and expanding awareness among healthcare providers. Europe follows closely, with a considerable market share attributed to growing acceptance of TMS as a clinical treatment for depression and other mental health conditions, as well as enhanced research initiatives focusing on TMS applications.

In the Asia Pacific region, the TMS market is set to experience rapid growth, with projected CAGR reaching 13.5% during the forecast period. This surge is catalyzed by rising investments in mental health awareness and initiatives by governmental bodies to support mental health treatment. Countries like Japan, China, and Australia are recognizing the importance of TMS as a viable treatment option, leading to increased adoption rates. Latin America and the Middle East & Africa represent emerging markets that are gradually increasing their share of the TMS market, driven by improving healthcare access and rising incidences of mental health disorders. As awareness and acceptance continue to grow, these regions are expected to contribute significantly to the overall TMS market in the coming years.

Opportunities

The opportunities for growth in the Transcranial Magnetic Stimulator market are abundant, particularly as advancements in technology continue to reshape treatment modalities. The development of portable TMS devices represents a significant opportunity, allowing patients to receive treatment in the comfort of their homes. This innovation addresses barriers related to access and affordability, creating potential for wider adoption of TMS therapies. Furthermore, ongoing research into the efficacy of TMS for a broader spectrum of indications, such as ADHD, PTSD, and substance use disorders, presents opportunities to expand its application scope. As more clinical evidence emerges supporting the use of TMS in these areas, healthcare providers are likely to increase their offerings, ultimately driving market growth.

Moreover, the increasing collaboration between research institutions and healthcare providers provides fertile ground for innovation in TMS therapies. This collaboration can lead to the development of new protocols and treatment algorithms, enhancing the effectiveness of TMS in various clinical settings. The growing emphasis on personalized medicine also presents an opportunity for TMS, as practitioners seek to tailor treatments to individual patient profiles. By leveraging advancements in neuroimaging and biomarker research, the TMS market can enhance treatment precision and outcomes. Ultimately, these factors combined suggest a robust future for the TMS market, with ample room for growth and innovation.

Threats

Despite the promising outlook for the Transcranial Magnetic Stimulator market, several threats could hinder its progress. One significant concern is the potential for regulatory hurdles that may arise as new TMS devices and protocols are introduced. Regulatory agencies' scrutiny can lead to delays in product approvals and increased costs for manufacturers, which may stifle innovation and market entry for new players. Additionally, the competitive landscape is becoming increasingly crowded, with numerous companies vying for market share. This heightened competition may lead to price wars, which could impact profitability for manufacturers and service providers in the TMS domain. The reliance on healthcare reimbursement for TMS treatments is another vulnerability; any changes or reductions in reimbursement policies could adversely affect patient access and market growth.

Furthermore, there is an inherent risk of adverse effects associated with TMS, such as headaches, scalp discomfort, or rare instances of seizures. These potential side effects can deter patients from opting for TMS, particularly if they have concerns about safety and efficacy compared to conventional treatments. The perception of TMS as a new or experimental therapy may also hinder uptake among both patients and healthcare providers, particularly in regions with lower levels of awareness and understanding of TMS benefits. Addressing these issues will be crucial for companies operating in the TMS market to ensure sustained growth and acceptance in the healthcare community.

Competitor Outlook

• NeuroStar TMS Therapy (NeuroStar, Inc.)
• MagVenture A/S
• BrainsWay Ltd.
• eNeura, Inc.
• Helius Medical Technologies, Inc.
• Neuronetics, Inc.
• Deep TMS (BrainsWay)
• Magstim Company Limited
• Repetitive Transcranial Magnetic Stimulation (rTMS) - Magstim
• Transcranial Magnetic Stimulation (TMS) - Neuronetics
• Axon TMS
• THYMOS - TMS Therapy
• MagVenture - TMS Solutions
• Inspiration TMS
• Stimwave Technologies

In the competitive landscape of the Transcranial Magnetic Stimulator market, several key players are making significant strides to establish their presence and differentiate their offerings. Companies such as NeuroStar, Inc. have positioned themselves as pioneers in the TMS space, with their NeuroStar TMS Therapy system being one of the first to receive FDA approval for treating depression. Their commitment to research and development has resulted in ongoing enhancements to their technology, making NeuroStar a formidable competitor. Similarly, BrainsWay Ltd. has made headlines with its innovative Deep TMS system, which leverages advanced coil technology to reach deeper brain structures and address conditions beyond depression, such as OCD and smoking cessation. This diversification into multiple indications strengthens their market position and appeal among practitioners.

MagVenture A/S is another noteworthy player in the TMS market, recognized for its focus on developing robust solutions for both research and clinical applications. Their portfolio includes a range of advanced TMS devices and software, allowing healthcare professionals to customize treatment protocols based on individual patient needs. The emphasis on providing comprehensive solutions, coupled with their commitment to continuous improvement, has allowed MagVenture to establish itself as a key competitor. Neuronetics, Inc. also deserves mention as they have demonstrated strong market performance through their innovative TMS devices and commitment to clinical evidence supporting their efficacy. Their focus on patient outcomes and expanding clinical indications positions them favorably within the market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Axon TMS
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 eNeura, Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 BrainsWay Ltd.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 MagVenture A/S
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Inspiration TMS
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Neuronetics, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Deep TMS (BrainsWay)
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 THYMOS - TMS Therapy
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Stimwave Technologies
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Magstim Company Limited
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 MagVenture - TMS Solutions
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Helius Medical Technologies, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 NeuroStar TMS Therapy (NeuroStar, Inc.)
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Transcranial Magnetic Stimulation (TMS) - Neuronetics
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Repetitive Transcranial Magnetic Stimulation (rTMS) - Magstim
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Transcranial Magnetic Stimulator Sales Market, By Application
    • 6.1.1 Depression
    • 6.1.2 Pain Management
    • 6.1.3 Neurology
    • 6.1.4 Psychiatry
    • 6.1.5 Others
  • 6.2 Transcranial Magnetic Stimulator Sales Market, By Product Type
    • 6.2.1 Repetitive Transcranial Magnetic Stimulation (rTMS)
    • 6.2.2 Theta Burst Stimulation (TBS)
    • 6.2.3 Deep Transcranial Magnetic Stimulation (dTMS)
    • 6.2.4 Quadripulse Stimulation (QPS)
    • 6.2.5 Others
  • 6.3 Transcranial Magnetic Stimulator Sales Market, By Distribution Channel
    • 6.3.1 Hospitals
    • 6.3.2 Specialty Clinics
    • 6.3.3 Ambulatory Surgical Centers
    • 6.3.4 Research Institutes
    • 6.3.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Transcranial Magnetic Stimulator Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Transcranial Magnetic Stimulator Sales market is categorized based on

By Product Type

• Repetitive Transcranial Magnetic Stimulation (rTMS)
• Theta Burst Stimulation (TBS)
• Deep Transcranial Magnetic Stimulation (dTMS)
• Quadripulse Stimulation (QPS)
• Others

By Application

• Depression
• Pain Management
• Neurology
• Psychiatry
• Others

By Distribution Channel

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Research Institutes
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• NeuroStar TMS Therapy (NeuroStar, Inc.)
• MagVenture A/S
• BrainsWay Ltd.
• eNeura, Inc.
• Helius Medical Technologies, Inc.
• Neuronetics, Inc.
• Deep TMS (BrainsWay)
• Magstim Company Limited
• Repetitive Transcranial Magnetic Stimulation (rTMS) - Magstim
• Transcranial Magnetic Stimulation (TMS) - Neuronetics
• Axon TMS
• THYMOS - TMS Therapy
• MagVenture - TMS Solutions
• Inspiration TMS
• Stimwave Technologies